aptorum group limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. the company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. it also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. aptorum group limited was incorporated in 2010 and is headquartered in london, the united kingdom.
Company profile
Ticker
APM
Exchange
Website
CEO
Ian Huen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
APM stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
30 Apr 24
6-K
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
30 Apr 24
6-K
Report of Foreign Private Issuer
6 Mar 24
6-K
Report of Foreign Private Issuer
22 Dec 23
6-K
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
21 Dec 23
6-K
Report of Foreign Private Issuer
30 Nov 23
6-K/A
Current report (foreign) (amended)
21 Nov 23
6-K
Report of Foreign Private Issuer
16 Nov 23
6-K
Report of Foreign Private Issuer
11 Sep 23
6-K
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
10 Aug 23
Latest ownership filings
SC 13D/A
Lui Darren
16 Apr 24
SC 13G/A
Hudson Bay Capital Management LP
2 Feb 24
SC 13D/A
Lui Darren
24 May 23
SC 13G
Hudson Bay Capital Management LP
7 Feb 22
SC 13D/A
HUEN IAN CHUNG YUEN
1 Jun 21
SC 13G
Hudson Bay Capital Management LP
8 Feb 21
SC 13D/A
HUEN IAN CHUNG YUEN
10 Mar 20
SC 13D/A
Aptorum Group Ltd
11 Jul 19
SC 13D/A
Aptorum Group Ltd
8 May 19
SC 13D/A
Aptorum Group Ltd
8 May 19
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 4 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 583.81 mm |
Total shares | 165.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Huen Ian Chung Yuen | 164.86 mm | $455.01 mm |
Lui Darren | 449.72 k | $1.64 mm |
Geode Capital Management | 36.47 k | $100.65 mm |
MS Morgan Stanley | 7.19 k | $19.41 mm |
Tower Research Capital | 2.63 k | $7.10 mm |
RY Royal Bank Of Canada | 1.00 | $0.00 |
Proequities | 0.00 | $0.00 |
News
Aptorum Gr FY EPS $(0.62) Up From $(2.75) YoY, Sales $431.38K Down From $1.30M YoY
30 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
15 Apr 24
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
20 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Mar 24